Reported Earlier, Seres Therapeutics To Present Preliminary PK/PD And Safety Data For Investigational Microbiome Therapeutic SER-155 At ASH 2023
Portfolio Pulse from Benzinga Newsdesk
Seres Therapeutics is set to present preliminary pharmacokinetics/pharmacodynamics (PK/PD) and safety data for its investigational microbiome therapeutic, SER-155, at the American Society of Hematology (ASH) 2023 conference.
December 08, 2023 | 7:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Seres Therapeutics' presentation of preliminary data for SER-155 at ASH 2023 could positively influence investor sentiment if the data is promising, potentially leading to a short-term uptick in MCRB's stock price.
The presentation of new data at a major conference often garners significant attention from investors and can lead to increased optimism if the results are favorable. As SER-155 is a key investigational asset for Seres Therapeutics, positive data could lead to a short-term rise in the stock price due to heightened investor interest and perceived potential for future revenue growth.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80